lansoprazole has been researched along with 5-hydroxylansoprazole in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Miura, M; Sugawara, K; Suzuki, T; Tada, H; Tateishi, T; Uno, T; Yasui-Furukori, N | 1 |
| Sugawara, K; Takahata, T; Tateishi, T; Uno, T; Yasui-Furukori, N | 2 |
| Gao, X; Hang, T; Song, M; Wen, A | 1 |
| Liu, H; Wang, G; Wang, X; Yang, M; Zhang, D | 1 |
| Babaoglu, MO; Balamtekin, N; Baysoy, G; Bozkurt, A; Demir, H; Gumus, E; Karaca, O; Uslu, N; Yasar, U; Yuce, A | 1 |
| Han, J; Liu, H; Liu, M; Wang, X; Yang, M; Zhang, D; Zhang, Y | 1 |
| Akdogan, A; Babaoglu, MO; Bertilsson, L; Bozkurt, A; Cevik, L; Goktas, MT; Kalkisim, S; Karaca, RO; Kilic, L; Yasar, U | 1 |
| Barlow, L; Beebe, J; Cui, Q; Danielson, J; Dong, Z; Huang, C; Josephraj, S; Li, X; Liu, JY; Nakshatri, H; Wang, CJ; Zhang, JT; Zhang, RH; Zhang, T | 1 |
2 trial(s) available for lansoprazole and 5-hydroxylansoprazole
| Article | Year |
|---|---|
Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Dexlansoprazole; Female; Genotype; Half-Life; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Stereoisomerism; Time Factors | 2004 |
Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Female; Humans; Infusions, Intravenous; Lansoprazole; Male; Proton Pump Inhibitors; Sex Characteristics; Young Adult | 2013 |
7 other study(ies) available for lansoprazole and 5-hydroxylansoprazole
| Article | Year |
|---|---|
Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Chromatography, High Pressure Liquid; Female; Humans; Lansoprazole; Male; Omeprazole; Reproducibility of Results; Sensitivity and Specificity; Sulfones | 2005 |
Lack of significant effect of grapefruit juice on the pharmacokinetics of lansoprazole and its metabolites in subjects with different CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Beverages; Chromatography, High Pressure Liquid; Citrus paradisi; Cross-Over Studies; Cytochrome P-450 CYP2C19; Female; Genotype; Half-Life; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Plant Extracts; Water | 2005 |
Simultaneous determination of lansoprazole and its metabolites 5'-hydroxy lansoprazole and lansoprazole sulphone in human plasma by LC-MS/MS: application to a pharmacokinetic study in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetates; Area Under Curve; Chromatography, Liquid; Drug Stability; Freezing; Guidelines as Topic; Half-Life; Humans; Indapamide; Lansoprazole; Metabolic Clearance Rate; Methanol; Molecular Structure; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; United States; United States Food and Drug Administration; Water | 2008 |
Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Asian People; China; Cytochrome P-450 CYP2C19; Humans; Lansoprazole; Male; Polymorphism, Single Nucleotide; Young Adult | 2011 |
Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Aryl Hydrocarbon Hydroxylases; Biotransformation; Child; Child, Preschool; Cytochrome P-450 CYP2C19; Female; Gene Frequency; Genetic Association Studies; Hospitals, Pediatric; Humans; Lansoprazole; Male; Omeprazole; Pharmacogenetics; Polymorphism, Genetic; Proton Pump Inhibitors; Turkey | 2012 |
Decreased Activity and Genetic Polymorphisms of CYP2C19 in Behçet's Disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents; Behcet Syndrome; Biotransformation; Case-Control Studies; Colchicine; Cytochrome P-450 CYP2C19; Down-Regulation; Gene Frequency; Genotype; Humans; Hydroxylation; Lansoprazole; Phenotype; Polymorphism, Genetic; Substrate Specificity; Turkey | 2017 |
Therapeutic Activity of the Lansoprazole Metabolite 5-Hydroxy Lansoprazole Sulfide in Triple-Negative Breast Cancer by Inhibiting the Enoyl Reductase of Fatty Acid Synthase.
Topics: Fatty Acid Synthases; Humans; Lansoprazole; Lipids; Oxidoreductases; Proton Pump Inhibitors; Sulfides; Triple Negative Breast Neoplasms | 2022 |